Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 11/20 | 0.50 |
| ▸ | CA12 | O43570 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11822062 | 0.85 | CA9 (0.54) | CA2CA5ACA9CA12CA1 | |
| SCHEMBL27711560 | 0.76 | CA2 (0.47) | CA2CA5ACA9CA12CA1 | |
| SCHEMBL13261334 | 0.75 | CA2 (0.53) | CA2CA5ACA9CA12CA1 | |
| SCHEMBL7133229 | 0.74 | CA9 (0.44) | CA2CA5ACA9CA12CA1 | |
| SCHEMBL26088269 | 0.73 | SMN1; SMN2 (0.56) | CA2CA9CA12CA1KMT2A | |
| Methoxymethane SCHEMBL10856175 | 0.71 | CA9 (0.41) | CA2CA5ACA9CA12CA1 | |
| SCHEMBL10371873 | 0.71 | CA2 (0.53) | CA2CA5ACA9CA12CA1 | |
| SCHEMBL922607 | 0.71 | CA9 (0.58) | CA2CA5ACA9CA12CA1 | |
| SCHEMBL7148444 | 0.71 | CA9 (0.53) | CA2CA9CA12CA1KMT2A | |
| SCHEMBL7130486 | 0.71 | CA2 (0.53) | CA2CA9CA12CA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160207928-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20160207928-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20160207928-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| WO-2014198594-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
| EP-1709023-B1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20070111988-A1 | Selective estrogen receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070066595-A1 | Selective estrogen receptor modulators | ARRAY BIOPHARMA, INC. | 2007-03-22 | — | — | US | disclosed |
| EP-1709023-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1709022-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073205-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073206-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| EP-0145252-B1 | INOTROPIC AGENTS | ELI LILLY AND COMPANY (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4533734-A | ANTICOAGULANTS, BRONCHODILATORS, VASODILATORS | ELI LILLY AND COMPANY (US) | 1985-08-06 | — | — | US | disclosed |
| EP-0145252-A1 | Inotropic agents | ELI LILLY AND COMPANY (US) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111988-A1 | Selective estrogen receptor modulators | ESR2, GPER1, ESRRA | CA2 210/4885CA5A 775/4885CA9 1110/4885 |
| US-20070066595-A1 | Selective estrogen receptor modulators | GPER1, ESR2, ESR1 | CA2 263/4885CA5A 739/4885CA9 1082/4885 |
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | CMA1, TPP1, TPSAB1 | CA2 3524/4885CA5A 2695/4885CA9 3659/4885 |
| US-20160207928-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BUB1B, PLK1, BRCA1 | CA2 4248/4885CA5A 3676/4885CA9 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.